Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Amir Snapir"'
Autor:
M. Luz, Mindaugas Jievaltas, Boris Alekseev, Aramis Investigators, Neal D. Shore, Toni Sarapohja, Sergey Polyakov, Iris Kuss, Karim Fizazi, Matthew R. Smith, Teuvo L Tammela, Marie-Aude Le Berre, Egils Vjaters, Amir Snapir, Oana Petrenciuc, Albertas Ulys
Publikováno v:
New England Journal of Medicine. 383:1040-1049
Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned primary analysis of a phase 3 trial, the median metastasis-free survival was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b560a14cdb95f452333c21d1df05938
https://doi.org/10.1056/nejmoa2001342
https://doi.org/10.1056/nejmoa2001342
Autor:
Toni Sarapohja, M. Luz, Iris Kuss, Aramis Investigators, Christian Kappeler, Matthew R. Smith, Amir Snapir, Boris Alekseev, Neal D. Shore, Teuvo L.J. Tammela, Mindaugas Jievaltas, Sergey Polyakov, Albertas Ulys, Karim Fizazi, Egils Vjaters
Publikováno v:
New England Journal of Medicine. 380:1235-1246
Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c0029bd4e0311354ae70175952dfcc6
https://doi.org/10.1056/nejmoa1815671
https://doi.org/10.1056/nejmoa1815671
Autor:
Toni Sarapohja, Matthew R. Smith, Albertas Ulys, Ateesha F. Mohamed, Egils Vjaters, Sergey Polyakov, Amir Snapir, Dawn Odom, Iris Kuss, Neal D. Shore, Mindaugas Jievaltas, Murilo Luz, Marie Aude Le Berre, Karim Fizazi, Teuvo L.J. Tammela, Jennifer Bartsch, Boris Alekseev
Publikováno v:
European journal of cancer (Oxford, England : 1990). 154
Background: In the ARAMIS trial, darolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT significantly improved metastasis-free survival (MFS), overall survival (OS) and time to pain progression in patients with non-metastatic ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b2f52eac8f8bb4d4ef64180f4eccdf4
https://pubmed.ncbi.nlm.nih.gov/34273811
https://pubmed.ncbi.nlm.nih.gov/34273811
Autor:
Toni Sarapohja, Neal D. Shore, Mutsushi Kawakita, Hiroya Mizusawa, Marie Aude Le Berre, Matthew R. Smith, Kazuhiro Suzuki, Masahiro Iinuma, Tetsuo Momma, Mototsugu Oya, Kazuki Kobayashi, Teuvo L.J. Tammela, Hiroji Uemura, Amir Snapir, Hirotsugu Uemura, Satoshi Fukasawa, Hisashi Matsushima, Nobuaki Matsubara, Iris Kuss, Ken-ichi Tabata, Tadahiro Kobayashi, Karim Fizazi, Hiroaki Nishimatsu
Publikováno v:
International Journal of Clinical Oncology
Background Darolutamide, an oral androgen receptor inhibitor, has been approved for treating nonmetastatic castration-resistant prostate cancer (nmCRPC), based on significant improvements in metastasis-free survival (MFS) in the ARAMIS clinical trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e6518b45933ebb3931b0d705c800ab1
https://trepo.tuni.fi/handle/10024/128183
https://trepo.tuni.fi/handle/10024/128183
Autor:
Toni Sarapohja, Egils Vjaters, M.W.H. Bögemann, Sergey Polyakov, Iris Kuss, N.D. Shore, Boris Alekseev, M-A. Le Berre, Mindaugas Jievaltas, M. Luz, T Tammela, Amir Snapir, Karim Fizazi, Albertas Ulys
Publikováno v:
European Urology Open Science, Vol 19, Iss, Pp e1389-e1390 (2020)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bacd2766955074ecd1883ae2e2ba89ac
http://www.sciencedirect.com/science/article/pii/S2666168320335163
http://www.sciencedirect.com/science/article/pii/S2666168320335163
Autor:
Johann S. de Bono, Petri Bono, John Aspegren, Sophie Postel-Vinay, Amir Snapir, Malaka Ameratunga, Irene Brana, Ruth Plummer, Timo Korjamo
Publikováno v:
British Journal of Cancer
Scientia
Scientia
BackgroundBromodomain and extra-terminal domain (BET) proteins are reported to be epigenetic anti-cancer drug targets. This first-in-human study evaluated the safety, pharmacokinetics and preliminary anti-tumour activity of the BET inhibitor ODM-207
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2306c38aafebd4ec618c7b751cd3d071
https://pubmed.ncbi.nlm.nih.gov/32989227
https://pubmed.ncbi.nlm.nih.gov/32989227
Autor:
Neal D. Shore, Matthew R. Smith, Toni Sarapohja, Boris Alekseev, Iris Kuss, Amir Snapir, Marie-Aude Le Berre, Albertas Ulys, Mindaugas Jievaltas, Sergey Polyakov, T Tammela, Murilo Luz, Egils Vjaters, Karim Fizazi
Publikováno v:
Journal of Urology. 201
INTRODUCTION AND OBJECTIVES:Asymptomatic nonmetastatic castrate-resistant prostate cancer (nmCRPC) patients (pts) would benefit from treatments (Tx) that delay disease progression with minimal Tx-r...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2df61922c24316a595456b1a75a35388
https://doi.org/10.1097/01.ju.0000557501.15711.19
https://doi.org/10.1097/01.ju.0000557501.15711.19
Autor:
N.D. Shore, M. Luz, Toni Sarapohja, Sergey Polyakov, Albertas Ulys, M-A. Le Berre, Amir Snapir, Iris Kuss, Matthew R. Smith, Boris Alekseev, T Tammela, Mindaugas Jievaltas, Oana Petrenciuc, Karim Fizazi, Egils Vjaters
Publikováno v:
Annals of Oncology. 31:S1328
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d90078cdc8ba788836ebf194d1b8c49
https://doi.org/10.1016/j.annonc.2020.10.443
https://doi.org/10.1016/j.annonc.2020.10.443
Autor:
Karim Fizazi, Marie-Aude Le Berre, Amir Snapir, T Tammela, Oana Petrenciuc, Albertas Ulys, Toni Sarapohja, Matthew R. Smith, Neal D. Shore, Murilo Luz, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Iris Kuss, Boris Alekseev
Publikováno v:
Journal of Clinical Oncology. 38:5514-5514
5514 Background: DARO is a structurally distinct androgen receptor inhibitor with a favorable safety profile, approved for treating men with nmCRPC after demonstrating significantly prolonged metastasis-free survival, compared with placebo (PBO), in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4fdac5dd6d1c5b3ff4ae3a0151c858b6
https://doi.org/10.1200/jco.2020.38.15_suppl.5514
https://doi.org/10.1200/jco.2020.38.15_suppl.5514
Autor:
Toni Sarapohja, Amir Snapir, Sergey Polyakov, Egils Vjaters, Mindaugas Jievaltas, J.S.-T. Pang, M. Luz, T Tammela, Matthew R. Smith, M.-A. Le Berre, Karim Fizazi, Iris Kuss, Albertas Ulys, N.D. Shore, Boris Alekseev
Publikováno v:
Annals of Oncology. 30:ix69
Background Asymptomatic nmCRPC patients (pts) would benefit from treatments (Tx) that delay disease progression and maintain quality of life (QoL), with minimal Tx-related adverse events (AEs). In ARAMIS, darolutamide (DARO) prolonged metastasis-free
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cdb99ced49c657f1f389320ce2d2de90
https://doi.org/10.1093/annonc/mdz424.001
https://doi.org/10.1093/annonc/mdz424.001